Veneta Tablet 10 mg contains Venetoclax 10 mg, a targeted oral anticancer medication designed for the treatment of hematologic malignancies, primarily chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Venetoclax is a BCL-2 inhibitor, a class of drugs that promotes apoptosis (programmed cell death) in cancer cells by blocking the BCL-2 protein, which is often overexpressed in malignant lymphocytes.

The 10 mg formulation is typically used as an initial starting dose during gradual dose escalation to reduce the risk of tumor lysis syndrome (TLS), a potentially life-threatening complication that can occur when a large number of cancer cells die rapidly. Veneta Tablet 10 mg allows oncologists to carefully titrate therapy while monitoring patient safety, making it suitable for relapsed, refractory, or high-risk CLL patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Venetoclax 10 mg per tablet

Mechanism of Action

Venetoclax in Veneta Tablet 10 mg works through:

1. Selective BCL-2 inhibition – BCL-2 is a protein that prevents apoptosis in cancer cells; Venetoclax blocks this protein, allowing programmed cell death.

2. Induction of apoptosis in malignant cells – Leads to rapid reduction of cancerous lymphocytes in the blood, bone marrow, and lymph nodes.

3. Tumor burden reduction – Helps shrink lymph node masses and lower peripheral blood lymphocyte counts.

4. Synergistic potential – Can be combined with monoclonal antibodies or chemotherapy agents for improved efficacy.

5. Targeted therapy – Minimizes damage to normal cells, reducing systemic toxicity compared to conventional chemotherapy.

This targeted mechanism makes Venetoclax highly effective for hematologic cancers with minimal impact on healthy tissues.

Indications

Veneta Tablet 10 mg is indicated for:

• Chronic lymphocytic leukemia (CLL) – Especially in patients with 17p deletion or relapsed/refractory disease

• Small lymphocytic lymphoma (SLL) – For patients who have not responded adequately to prior therapy

• Combination therapy – Used with rituximab or obinutuzumab in first-line or relapsed treatment regimens

• High-risk hematologic malignancies – Providing precision therapy in aggressive or resistant cases

This low-dose formulation is used under strict medical supervision as part of a dose-escalation protocol to ensure patient safety.

Dosage and Administration

• Starting dose: 10 mg once daily, as part of a gradual dose escalation schedule

• Administration: Swallow the tablet whole with water; may be taken with or without food

• Titration: Dose gradually increased to therapeutic levels (typically up to 400 mg daily) to reduce TLS risk

• Monitoring: Regular blood tests to track white blood cell counts, kidney function, and electrolytes during dose escalation

• Duration: Continue until disease progression or unacceptable toxicity occurs

Benefits

• Safe and controlled starting dose for hematologic malignancy therapy

• Promotes apoptosis in cancer cells, reducing tumor burden

• Effective for high-risk, relapsed, or refractory CLL and SLL

• Can be combined with other therapies for enhanced cancer control

• Oral administration allows convenient outpatient therapy

Precautions

• Monitor for tumor lysis syndrome (TLS) during initial dosing

• Caution in patients with renal or hepatic impairment

• Pregnancy and breastfeeding: Contraindicated due to risk to the fetus

• Do not discontinue therapy abruptly; consult a physician for dose adjustments

• Potential drug interactions with CYP3A inhibitors or inducers; inform the doctor of all medications

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects:

• Nausea, vomiting, or diarrhea

• Fatigue or mild headache

• Low blood counts (neutropenia, anemia, thrombocytopenia)

Serious side effects:

• Tumor lysis syndrome (TLS)

• Severe infections due to neutropenia

• Liver enzyme elevations

• Rare allergic reactions

Immediate medical attention is required for severe bleeding, sudden kidney issues, or high fever.

Storage

• Store below 25°C in a cool, dry place

• Protect from light and moisture

• Keep tablets in original blister packaging

• Keep out of reach of children

Veneta Tablet 10 mg provides a safe and precise starting dose for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, enabling careful dose escalation and effective cancer cell apoptosis while minimizing potential complications.